TRIP13

Across TCGA pan-cancer cohorts, TRIP13 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRIP13 data layer compared with 30 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRIP13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIP13 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where TRIP13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.214	0.755	<.001	55	view →
PDAC	OS	Median	III,IV	0.244	0.660	<.001	39	view →
LUAD	OS	Median	II,III,IV	0.327	0.844	.005	10	view →
GBM	DFS	Median	All	0.636	0.790	.022	3	view →
UCEC	DFS	Median	All	0.782	0.915	.032	2	view →
LSCC	OS	Median	II,III,IV	0.875	0.678	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRIP13–CCRCC (DFS)

Open the CCRCC breakdown →